FogPharma
Marie Nguyen, M.D. has a diverse and extensive work experience in the field of medicine. Marie started as a Medical Student at Stanford University in 2001 and eventually became a Hematology and Oncology Fellow at Stanford University School of Medicine. Marie worked as an Internal Medicine Resident at the University of Washington/Fred Hutchinson Cancer Research Center before transitioning into academia as an Assistant Professor at the University of Michigan. Dr. Nguyen also held roles at The Janssen Pharmaceutical Companies of Johnson & Johnson and Celgene before joining Bristol Myers Squibb as a Senior Director in Early Clinical Development. Most recently, they served as the VP, Head of Clinical Development at FogPharma.
Marie Nguyen, M.D. (Roussillon) completed their Bachelor's degrees in Biological Sciences and Classical and Ancient Studies at Stanford University in 2000. Marie then went on to earn their M.D. in 2006 from Stanford University School of Medicine. In 2013, they obtained a Master's degree in Epidemiology from Stanford University School of Medicine. Additionally, they hold a certification in Hematology from the American Board of Internal Medicine.
This person is not in any offices
FogPharma
1 followers
FogPharma is dedicated to the creation of a new class of medicines that target human disease drivers currently considered “undruggable.” The company’s cell-penetrating miniproteins (CPMPs) combine the targeting power of protein therapeutics with the cell-penetrating ability of small molecules. This unique combination of targeting features enables CPMP’s to access and engage proteins that have long been known to play a major role in causing serious human diseases, but have been frustratingly beyond the reach of therapeutic intervention.